10/17/2016, 5:30PM: Now you see it; Now you see it better: Advances in
Imaging for Medical Applications
Imaging and vision systems are being used for discovery of cells, to new material development, to diagnostic procedures, therapies and surgery.
Tonight we cover them all and include advances in miniaturization, wavelengths of light, and robot guidance. See what can be detected, new applications and diagnostics that are enabled.
Eman Namati has been involved in image processing and optics across the light spectrum —xray, laser, fiber optic, infrared —and has seen the advances, the challenges, and the opportunities that still exist for creating products that enhance medicine.
Eman will provide an overview of the types of imaging, the biological/imaging structures each enables, and where the industry is now. This will be follow by each of the panelists explaining their company, and work.
Moderated by Lew Harrold, Innovative Medical Consultants, with:
- Eman Namati, VP R&D, NinePoint Medical, Keynotes
- Yuxiang (Shawn) Liu, Assistant Professor, Worcester Polytechnic Institute
- Lionel Bouchet, VP Product Marketing, Mevion
- Liz Asai, CEO and founder of 3Derm Systems
Eman Namati, PhD, is Vice President of Research and Development at NinePoint Medical in Bedford, MA. As a founding member of the company in 2010, he brought extensive scientific and technical expertise in the fields of medical imaging. Prior to joining NinePoint, Eman was a post-doctoral research fellow at Massachusetts General Hospital and Harvard Medical School working with Profs. Gary Tearney and Brett Bouma on the development of Optical Coherence Tomography – the core technology that was licensed to NinePoint. He helped build and lead the product development team, translating this academic technology into a commercial medical device in less than 3 years.
Eman has authored and coauthored over 50 scientific publications, abstracts and book chapters in the fields of signal processing, computed tomography, multi-modal imaging and biomedical optics. In addition, he has numerous patents related to optical imaging technologies. Eman holds a PhD in Biomedical Engineering through a dual program with Flinders University Australia and the University of Iowa as an APA(Australian Post-graduate award) and ISATNA(Iowa/South Australian Transnational Alliance) fellowship recipient. He received a double undergraduate degree in Engineering (BE) and Science (BSc) from Flinders University Australia.
Yuxiang (Shawn) Liu is an assistant professor in Mechanical Engineering who joined WPI in 2013. He received a Ph.D. in Mechanical Engineering from University of Maryland, College Park in 2011. Before joining WPI, Yuxiang Liu worked as a postdoctoral researcher in Purdue University in 2011. He worked at National Institute of Standards and Technology (NIST) as a NIST-ARRA fellow from 2011 to 2013. His research interests include fiber based optical trapping, silicon nanomechanics and nanophotonics, optofluidics, fiber optical sensors, bioinspired soft robotics, and cell mechanics. His research has been published on journals including Nature Nanotechnology, Physical Review Letters, Optics Letters, and Biomedical Optics Express.
Lew Harrold is an accomplished Medical Device Realization Professional with over 40 years’ experience of product lifecycle management of Medical Devices for a world-wide market. His experience encompasses multidisciplinary development team leadership, project management, engineering, clinical evaluation, manufacturing and medical device regulatory submissions for markets in US, Latin America, China and Japan. Lew has well developed business acumen and has a proven track record of bringing well designed and reliable products to market in a timely manner.
Throughout his career, Lew has managed and executed successful product development programs in radiology imaging, disposable whole blood optical devices, invasive and non-invasive cardiac output, patient vital signs monitoring and home health care remote monitoring. Additionally, he has assisted companies in the realization of new medical technologies, including clinical testing and medical research.
A graduate of Carnegie Mellon University, a certified PMP, and a member of PMI, IEEE and PDMA, Lew is an expert in medical product design, biomedical engineering team development, program management, Quality Function Deployment (QFD) and clinical studies. Lew has deployed his expertise to realize profitable medical products for companies ranging in size from startups to Fortune 500. These commercialized products included 8 patents, 30+ successful 510(k)s, and 16 new medical products.
Lionel Bouchet, PhD, is VP of Product Management and Marketing at Mevion Medical Systems in Littleton. Prior to joining the startup team at Mevion (formerly Still River Systems), Lionel held similar roles at Varian Medical Systems and ZMed.
Lionel specializes in image-guided medical systems and was an Assistant Professor in the Dept. of Neurological Surgery at University of Florida. Mevion Medical Systems is a leading provider of proton therapy systems for use in radiation treatment for cancer patients and uses imaging to locate the treatment site.
Dr. Bouchet has degrees in Physics - Nuclear Engineering from Institut National Polytechnique de Grenoble, MS, Nuclear Engineering and Medicine from Texas A&M University, and PhD, Medical Physics from University of Florida.
Liz Asai is the CEO and co-founder of 3Derm Systems. While studying biomedical engineering at Yale, Liz and her co-founder invented a 3D skin-imaging device that allows a dermatologist to see a patient remotely and triage skin concerns. In 2013, the team was awarded a National Science Foundation SBIR Award, making Liz the youngest recipient of the award in history.
Liz is actively involved with local and national health tech policy groups drafting testimony and legislation advocating for telemedicine reimbursement. She serves as a mentor in the startup community and writes guides to help new entrepreneurs through the grant writing process. Liz has been featured in Boston.com’s 25 Under 25 and Boston MedTech’s 40 Under 40. She holds a Bachelor of Science (BS), Bioengineering and Biomedical Engineering form Yale University.
November 14, 2016: Antimicrobials: Reducing Need for Antibiotics
What will kill more people than cancer? What will cost us over $100 trillion dollars unless we develop antimicrobial resistance alternatives soon? Preventing infections from spreading is one alternative. Developing new ways to kill bacteria and fungi is another. Experts taking each path will explain.
Getting an infection is bad enough, but getting one while in a hospital’s clean environment should be unheard of. Healthcare-associated infections (HAIs) – infections patients can get while receiving medical treatment in a healthcare facility–are a major, yet often preventable, threat to patient safety. In 2011, there were an estimated 722,000 HAIs in U.S. acute care hospitals. Additionally, about 75,000 patients with HAIs died during their hospitalizations. When healthcare facilities, care teams, and individual doctors and nurses are aware of infection problems and take specific steps to prevent them, rates of some targeted HAIs (e.g., Central Line Associated Blood Stream Infections, CLABSI) can decrease by more than 70 percent. But despite better efforts, between 2009 and 2014 there was no change in overall catheter-associated urinary tract infections (CAUTI).
Lisa Maloney of Sciessent LLC will teach us how applying an antimicrobial coating to surfaces that patients and hospital people touch can reduce the transmission of infections within a healthcare facility. These antimicrob-ials can also be mixed into the materials of medical devices to prevent bacteria from colonizing the devices.
Todd Alexander of AMProtection will explain why chemically binding a bacteria-killing molecule to the surfaces of urinary catheters can prevent catheter-associated urinary tract infections. These bound antimicrobial peptides are not consumed while killing bacteria, so last a long time and could not only prevent CAUTI but reduce the frequency of uncomfortable urinary catheter changes.
Our panel shares their company’s advances and where the state-of-the-art is taking us.
- Lise Moloney, Director, Business Development – Healthcare, Sciessent LLC
- Todd Alexander, CEO and Co-Founder, AMProtection
- Lindsay Lozeau, AMProtection
- Brad Prosek is President of All Terrain bioPartners
Todd Alexander is CEO and Co-Founder of AMProtection, and is a Fellow at The University Innovation Fellows program is managed by the National Center for Engineering Pathways to Innovation (Epicenter). Todd holds a BS and MS in Chemical Engineering from WPI.
Lindsay Lozeau, a PhD candidate in chemical engineering at WPI, is co-founder and Chief Technology Officer of AMProtection. She has been awarded two fellowships (NSF IGERT and Hitchcock) and has made two first place elevator pitches at WPI and one at The Venture Forum in Worcester. She also has industry experience working at Kimball Physics, Inc. and TEI Biosciences. Currently her PhD work, aimed toward the use and delivery of antimicrobial peptides in collagen-based wound dressings, is funded under an NSF STTR grant and is nearing license.She holds a BS in Chemical Engineering from URI and is in the PhD program at WPI.
Lise Moloney has over 15 years of experience in the antimicrobial additive and medical device fields in both R&D and business development. Her experience includes market development, product development, technology assessment and regulatory strategy. At Sciessent, Lise plays a key role in strategic planning and execution of marketing the company’s Agion antimicrobial technology to the healthcare industry. Prior to joining Sciessent Lise was with Covidien, where she held several R&D positions, including Group Leader in Advanced Research, vetting new technologies and establishing Clinical Advisory Boards to guide and support advanced research programs.
Brad Prosek is President of All Terrain bioPartners LLC, a life sciences advisory group, and was previously Head, Infection Prevention Technology & Services, for Cubist Pharmaceuticals, broadening the solutions Cubist could deliver to hospital systems fighting the rising tide of antibiotic-resistant bacteria. Before that he served as Senior Director, Corporate Development for Cubist Pharmaceuticals, Inc. In this role, Brad focused on transactions supporting Cubist’s drug pipeline build-out. Previously at Cubist, Brad started and led the Market Access group, which focused on developing non-hospital markets for the company’s flagship product CUBICIN (daptomycin for injection). He joined Cubist in 2005 from Biogen Idec, Inc., bringing ten years of global healthcare strategy, operating, and consulting experience. Brad holds an M.B.A. from Columbia Business School and a B.S.F.S from Georgetown University’s Walsh School of Foreign Service.
Committee: Jerry Shapiro, Mark Hediger, Amy LaChapelle, Carmel Denis, Howard Lin
Co-Chairs, Jerry Shapiro and Barbara Finer
Contact our Chair with questions or if you want to volunteer in some capacity (Jerrold)